CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

​On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

Related Keywords

California ,United States ,San Diego ,University Of California San Diego ,Mariat Millan ,Ezra Cohen ,Charles Prussak ,Emily Henderson ,California Institute For Regenerative Medicine ,Oncology At Moores Cancer Center ,Uc San Diego Health ,Uc San Diego School Of Medicine ,Division Of Hematology ,Solid Tumor Therapeutics Program ,Moores Cancer Center ,San Diego Center ,California Institute ,Regenerative Medicine ,California San Diego School ,Diego School ,Diego Health ,Cell Therapy Translational Laboratory ,Moores Cancer ,Blood ,Dancer ,Fell ,Immunotherapy ,Ntibody ,Ntigen ,Cancer Therapy ,Cart Cell ,Chimeric Antigen Receptor ,Laboratory ,Leukemia ,Medicine ,Eceptor ,Research ,T Cell ,Humor ,